Skin eruption on a 9-year-old
FDA accepts sNDA for roflumilast cream 0.15% to treat atopic dermatitis
The FDA has accepted a supplemental New Drug Application (sNDA) for roflumilast cream 0.15% for the treatment of atopic dermatitis (AD) in children aged 6 years and up.
Recognize & Refer: Hemangiomas in pediatrics
Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Worsening severity of AD in children associated with increased comorbidity onset risk
Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
Treating Patients with Trichotillomania and Other Related Behaviors
Dr Jon E. Grant talks about the genetics, neurobiology, and cognitive processes of body-focused repetitive behaviors, which include trichotillomania, skin picking, and other behaviors.
A 13-year-old girl with well-demarcated rash on back and chest
A healthy 13-year-old girl presented with a 1-month history of an asymptomatic, well-demarcated rash on her back and upper chest. The eruption consisted of discrete, dark brown papules that coalesced into large, flat-topped plaques with mild superficial scale and accentuation of skin markings. What's the diagnosis?
Tapinarof cream 1% reduces itch as early as 24 hours after application for pediatric AD
A rapid reduction in pruritis as early as 24 hours after first application was announced as new positive data from a pair of identical, phase 3 studies of tapinarof cream 1% in children as young as 2 years and adults with atopic dermatitis (AD).
2 Clarke Drive Cranbury, NJ 08512